TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI lessened its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 77.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,111 shares of the company’s stock after selling 3,750 shares during the quarter. Arcadia Investment Management Corp MI’s holdings in TransMedics Group were worth $88,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Cutler Group LLC CA raised its position in shares of TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after acquiring an additional 600 shares in the last quarter. RiverPark Advisors LLC acquired a new stake in shares of TransMedics Group during the 3rd quarter worth approximately $60,000. First Horizon Advisors Inc. boosted its position in TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares during the period. Van ECK Associates Corp grew its stake in TransMedics Group by 39.0% during the 3rd quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock worth $116,000 after buying an additional 597 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in TransMedics Group in the third quarter worth $180,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on TMDX shares. Morgan Stanley upped their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. boosted their price objective on TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Oppenheimer raised their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Piper Sandler reiterated an “overweight” rating and set a $120.00 price target (up previously from $95.00) on shares of TransMedics Group in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group increased their price target on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $119.00.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 10,000 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $82.99, for a total value of $829,900.00. Following the sale, the insider now directly owns 26,502 shares in the company, valued at approximately $2,199,400.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Tamer I. Khayal sold 10,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $82.99, for a total transaction of $829,900.00. Following the transaction, the insider now directly owns 26,502 shares in the company, valued at $2,199,400.98. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,044,932.83. The disclosure for this sale can be found here. Insiders sold 295,889 shares of company stock worth $31,623,584 in the last quarter. Insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

TransMedics Group stock traded up $1.55 during trading hours on Thursday, reaching $128.77. 1,098,209 shares of the company were exchanged, compared to its average volume of 771,907. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of -378.74 and a beta of 1.87. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $132.96. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The stock has a 50-day moving average of $89.25 and a 200 day moving average of $79.26.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.08) earnings per share. As a group, research analysts anticipate that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.